Maiorano V, Chianese R, Fumarulo R, Costantino E, Contini M, Carnimeo R, Cazzola P
Department of Physiopathology, University of Bari, Italy.
Int J Tissue React. 1989;11(1):21-5.
Thymomodulin is an immunomodulating agent which is derived from calf thymus by partial acid lysis. It promotes T-cell maturation, enhances antibody synthesis and improves the phagocytic response of neutrophils. Clinical trials have revealed the effectiveness of this thymic derivative in the prevention of recurrent respiratory infections (RRI) in children and in adults; 11 patients (8 males and 3 females; age range 18-76 years) with chronic bronchitis dominated by recurrent respiratory infections were studied. They were treated orally for 6 months during the winter season with 120 mg/day of thymomodulin. All the subjects were asked to keep a diary recording the intensity of their symptoms, the number of working days lost (days of illness) and the use of antibiotic and/or mucolytic drugs. At the beginning and at the end of the trial each patient was subjected to a control with a flexible fibreoptic bronchoscope with bronchoalveolar lavage to evaluate the phagocytic response of alveolar macrophages. At the end of therapy a significant improvement of the clinical status, evaluated by the above-mentioned parameters, of the bronchial mucosa aspect and an increase in alveolar macrophage superoxide production was noticed (from 0.1 +/- 0.09 and 0.8 +/- 0.5 nmol to 1.6 +/- 0.8 and 4.1 +/- 2.2 nmol with PMA or zymosan particles respectively; p less than 0.001). During thymomodulin treatment no side-effects were recorded.
胸腺调节素是一种免疫调节剂，通过部分酸解从小牛胸腺中提取。它促进T细胞成熟，增强抗体合成，并改善中性粒细胞的吞噬反应。临床试验表明，这种胸腺衍生物对预防儿童和成人反复呼吸道感染（RRI）有效；对11例以反复呼吸道感染为主的慢性支气管炎患者（8例男性，3例女性；年龄范围18 - 76岁）进行了研究。在冬季，他们口服120毫克/天的胸腺调节素，持续治疗6个月。所有受试者都被要求记录症状强度、误工天数（患病天数）以及抗生素和/或黏液溶解药物的使用情况。在试验开始和结束时，对每位患者使用可弯曲纤维支气管镜进行支气管肺泡灌洗检查，以评估肺泡巨噬细胞的吞噬反应。治疗结束时，通过上述参数评估发现临床状况有显著改善，支气管黏膜状况改善，肺泡巨噬细胞超氧化物生成增加（分别用佛波酯或酵母聚糖颗粒刺激时，从0.1±0.09和0.8±0.5纳摩尔增加到1.6±0.8和4.1±2.2纳摩尔；P < 0.001）。在胸腺调节素治疗期间未记录到副作用。
